Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • ADVENTRX Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amylin Pharmaceuticals Inc.
  • Aradigm Corp.
  • Ariad Pharmaceuticals Inc.
  • Astex Pharmaceuticals Inc.
  • Celgene Corp.
  • Galena Biopharma Inc.
  • Infinity Pharmaceuticals Inc.
  • MannKind Corp.
  • Onyx Pharmaceuticals Inc.
  • Pharmacyclics Inc.
  • Synta Pharmaceuticals Corp.
  • Ventrus Biosciences, Inc.
  • Vivus Inc.

Michael King

JMP Securities

Image: Michael King

Michael G. King Jr. is a managing director and senior biotechnology analyst at JMP Securities. King comes to JMP from Rodman & Renshaw LLC, where he was managing director and senior biotechnology analyst. He has more than 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellside research survey, in addition to being named that publication's "Home Run Hitter" in 2000. King also served as senior vice president of corporate development and communication at ZIOPHARM Oncology (ZIOP:NASDAQ). Prior to joining ZIOPHARM, King was a managing director and senior biotechnology snalyst at Wedbush Securities. He holds a bachelor's degree in finance from Baruch College.



Recent Interviews

The Life Sciences Report Watchlist 2013 (1/31/13) Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months.

Which Six Companies Are in Michael King's Oncology Wheelhouse? (1/10/13) JMP Securities Managing Director and Senior Biotechnology Analyst Michael King Jr. never recoils from the most sophisticated science. He's always been partial to oncology indications and to new technologies that disrupt old paradigms and usher in the new. King has the kind of stock-picking track record that merits attention, and in this interview with The Life Sciences Report, he brings six important ideas to the table for investors to consider.

Recent Quotes

"We reiterate our Market Outperform rating on ASTX." (4/30/13) Astex Pharmaceuticals Inc. - Michael King, JMP Securities More >